BNTX vs DGX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BNTX shows bearish fundamentals based on deterministic rules. Financial strength is weak (F-Score 2/9). Concerns include weak profitability or high valuation.
DGX exhibits stable fundamental health with a Piotroski F-Score of 6/9 and a sustainable dividend payout ratio of 36.02%. While the company shows consistent earnings growth (15.5% YoY) and a long track record of beating estimates, it is currently caught between a conservative Graham Number ($115.21) and a growth-based Intrinsic Value ($266.98). The bullish fundamental outlook is heavily offset by a 0/100 technical trend and bearish insider sentiment, with 10 sell transactions and zero buys in the last six months. Consequently, the stock appears fundamentally sound but lacks immediate price momentum.
Compare Another Pair
Related Comparisons
BNTX vs DGX: Head-to-Head Comparison
This page compares BioNTech SE (BNTX) and Quest Diagnostics Incorporated (DGX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.